Clay Siegall’s father made quite the impression on his son. When Clay was 19 his father was diagnosed with cancer. The resulting five year fight with cancer resulted in Mr. Siegall losing his father when Clay was just 24. From that moment on Clay has made it his mission to help those suffering from cancer. And given his school studies and work tract record, he is a man of his word.
Mr. Siegall has two degrees, one is a Bachelor’s degree in Zoology from the University of Maryland then other is his PhD in Genetics from George Washington University. With his PhD firmly in place, Clay started working for the National Cancer Institute and, after a few years, Bristol Meyers Squib Pharmaceutical Research Institute. After years of working research, Clay became frustrated that all of the work he was doing was not profitting him, except as a paycheck. Also Mr. Siegall did not have any proprietary rights over anything that he was developing for the company. That is when Mr. Siegall decided to open Seattle Genetics in 1998.
Seattle Genetics was started with a skeleton crew and Clay’s ideals in believing that they could make cancer patients lives better with therapies other than traditional cancer treatment. The first few years of Seattle Genetics history are pretty rough, but Mr. Siegall never stopped working hard. As is the case with new startups, they need to prove themselves and Seattle Genetics has done just that. With the success and production of “ADCetris” a antibody drug conjugate (ADC), Seattle Genetics has started seeing real progress alternative cancer treatments. ADCetris plus a couple other successful pharmaceuticals have helped keep Seattle Genetics operating in the black and researching for the alternative treatment for cancer.
Clay now spends most of his time securing funding for his much larger community of researchers and support staff that keeps Seattle Genetics on the cutting edge of cancer research. To read more about Clay Siegall, please click here.